Relationship between interleukin-12-expressing cells and antigen-presenting cells in patients with colorectal cancer

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3541-3546

  Inoue, Yuzuru ^a,b   Nakayama, Yoshifumi ^a   Minagawa, Noritaka ^a   Katsuki, Takefumi ^a   Nagashima, Nobuo ^a   Matsumoto, Kentaro ^a   Shibao, Kazunori ^a   Tsurudome, Yosuke ^a   Hirata, Keiji ^a   Nagata, Naoki ^a   Itoh, Hideaki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Antigen presenting cell; CD68; CD83; Colorectal cancer; Dendritic cell; IL 12; Macrophage

Indexed keywords

CD68 ANTIGEN; CD83 ANTIGEN; INTERLEUKIN 12;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MACROPHAGE; MALE; PRIORITY JOURNAL; PROGNOSIS; STROMA; TUMOR VOLUME;

ADULT; AGED; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-12; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING;

EID: 23344447556     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma VM: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324, 1997.
2. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA and Moreno M: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79: 2320-2328, 1997.
3. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y and Gabbert HE: Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 10(2): 309-313, 2003.
4. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
5. Fong L and Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245-273, 2000.
6. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M and Engelhard VH: Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21(21): 4016-4026, 2003.
7. Avigan D: Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res 10: 6347S-6352S, 2004.
8. Mantovani A: Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest 71: 5-16, 1994.
9. Ohno S, Suzuki N, Ohno Y, Inagawa H, Soma G and Inoue M: Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res 23(6a): 4395-4409, 2003. Review.
10. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D and Nickbarg E: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 176(5): 1387-1398, 1992.
11. Chensue SW, Ruth JH, Warmington K, Lincoln P and Kunkel SL: In vivo regulation of macrophage IL-12 production during type 1 and type 2 cytokine-mediated granuloma formation. J Immunol 155(7): 3546-3551, 1995.
12. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM and O'Garra A: Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154(10): 5071-5079, 1995.
13. Maldonado-Lopez R, Maliszewski C, Urbain J and Moser M: Cytokines regulate the capacity of CD8alpha(+) and CD8alpha(-) dendritic cells to prime Th1/Th2 cells in vivo. J Immunol 167(8): 4345-5430, 2001.
14. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3(2): 133-146, 2003.
15. Murphy KM and Reiner SL: The lineage decisions of helper T cells. Nat Rev Immunol 2(12): 933-944, 2002.
16. Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM and Hamilton TA: Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 156(2): 693-699, 1996.
17. Atkins MB, Robertoson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H and Sherman ML: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3: 409-417, 1997.
18. Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H and Bukowski R: Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4: 1183-1191, 1998.
19. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C and Prieto J: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22(8): 1389-1397, 2004.
20. Sobin LH and Wittekind CN: International Union Against Cancer. TNM Classification of Malignant Tumors, 6th ed. New York: John Wiley & Sons, Inc: 2002.
21. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, Parmiani G, Trinchieri G and Colombo MP: CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 25: 137-146, 1995.
22. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993.
23. Shibata M, Nezu T, Takekawa M, Takizawa H, Ando K, Miyake H, Amano S and Kurosu H: Serum levels of interleukin-10 and interleukin-12 in patients with colorectal cancer. Ann N Y Acad Sci 795: 410-412, 1996.
24. O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, Kerin MJ, Lee PW and Monson JR: Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 4(8): 1943-1948, 1998.
25. Tsuboi K, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Manda R, Fukuchi M, Kato H and Kuwano H: Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett 205(2): 207-214, 2004.
26. Shibata M, Nezu T, Kanou H, Abe H, Takekawa M and Fukuzawa M: Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34: 416-420, 2002.
27. Morita Y, Yamamura M, Nishida K, Harada S, Okamoto H, Inoue H, Ohmoto Y, Modlin RL and Makino H: Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 41: 306-314, 1998.
28. Sakkas LI, Johanson NA, Scanzello CR and Platsoucas CD: Interleukin-12 is expressed by infiltrating macrophages and synovial lining cells in rheumatoid arthritis and osteoarthritis. Cell Immunol 188: 105-110, 1998.
29. Gorak PM, Engwerda CR and Kaye PM: Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 28: 687-695, 1998.
30. Paleri V, Pulimood A, Davies GR and Birchall MA: Interleukins 7 and 12 are expressed in head and neck squamous cancer. Clin Otolaryngol 26: 302-306, 2001.
31. Nakayama Y, Inoue Y, Nagashima N, Katsuki T, Matsumoto K, Shibao K, Tsurudome K, Hirata K, Sako T, Nagata N and Itoh H: Relationships between local and systemic expression of interleukin-12 and plasma levels of vascular endothelial growth factor in patients with gastric cancer. Anticancer Res 24(5C): 3289-3294, 2004.
32. Poindexter NJ, Sahin A, Hunt KK and Grimm EA: Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 6: R408-415, 2004.
33. Schwaab T, Weiss JE, Schned AR and Earth RJ Jr: Dendritic cell infiltration in colon cancer. J Immunother 24: 130-137, 2001.
34. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, Gon G, Toyoda M and Tanigawa N: Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104(1): 92-97, 2003.
35. Nakayama Y, Nagashima N, Minagawa N, Inoue Y, Katsuki T, Onitsuka K, Sako T, Hirata K, Nagata N and Itoh H: Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 22(6C): 4291-4296, 2002.
36. Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, Hoefler G, Klimpfinger M, Denk H and Zatloukal K: Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch 445(2): 160-167, 2004.